JP2002514053A5 - - Google Patents

Download PDF

Info

Publication number
JP2002514053A5
JP2002514053A5 JP1998514774A JP51477498A JP2002514053A5 JP 2002514053 A5 JP2002514053 A5 JP 2002514053A5 JP 1998514774 A JP1998514774 A JP 1998514774A JP 51477498 A JP51477498 A JP 51477498A JP 2002514053 A5 JP2002514053 A5 JP 2002514053A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1998514774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002514053A (ja
Filing date
Publication date
Priority claimed from US08/928,958 external-priority patent/US5877282A/en
Application filed filed Critical
Publication of JP2002514053A publication Critical patent/JP2002514053A/ja
Publication of JP2002514053A5 publication Critical patent/JP2002514053A5/ja
Withdrawn legal-status Critical Current

Links

JP51477498A 1996-09-20 1997-09-15 核局在化配列を持つ、核タンパク輸送のペプチド阻害物質およびその使用方法 Withdrawn JP2002514053A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2697896P 1996-09-20 1996-09-20
US60/026,978 1996-09-20
US08/928,958 1997-09-12
US08/928,958 US5877282A (en) 1996-09-20 1997-09-12 Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
PCT/US1997/016217 WO1998011907A1 (en) 1996-09-20 1997-09-15 Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2002514053A JP2002514053A (ja) 2002-05-14
JP2002514053A5 true JP2002514053A5 (enExample) 2005-04-07

Family

ID=26701884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51477498A Withdrawn JP2002514053A (ja) 1996-09-20 1997-09-15 核局在化配列を持つ、核タンパク輸送のペプチド阻害物質およびその使用方法

Country Status (7)

Country Link
US (1) US5877282A (enExample)
EP (1) EP1015012A4 (enExample)
JP (1) JP2002514053A (enExample)
AU (1) AU731725B2 (enExample)
CA (1) CA2265571A1 (enExample)
TW (1) TW575580B (enExample)
WO (1) WO1998011907A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US7553929B2 (en) * 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
GB9708676D0 (en) * 1997-04-30 1997-06-18 Imp Cancer Res Tech Chemical compounds
GB2337329B (en) * 1997-04-30 2001-09-05 Imp Cancer Res Tech Inhibitors of nuclear protein/nuclear receptor interaction
CA2350919A1 (en) * 1998-11-13 2000-05-25 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
AU5269800A (en) * 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in allergy cells
WO2001000677A1 (en) 1999-06-28 2001-01-04 The University Of Newcastle Research Associates Limited A method of modulating integrin mediated cellular activity and agents useful for same
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
US6312956B1 (en) 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
AU785007B2 (en) * 1999-11-24 2006-08-24 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
CA2399676C (en) * 2000-02-07 2010-04-06 Wisconsin Alumni Research Foundation Pharmacologically active antiviral peptides and methods of their use
EP1862471A3 (en) * 2000-02-07 2008-05-28 Wisconsin Alumni Research Foundation Pharmacologically active antiviral peptides and methods of their use
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
EP1379540A4 (en) * 2001-04-19 2005-11-16 Bristol Myers Squibb Co POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH NF-KB PATH
US20040086896A1 (en) * 2001-04-19 2004-05-06 Julie Carman Polynucleotides and polypeptides associated with the NF-kB pathway
DE60335101D1 (de) * 2002-04-25 2011-01-05 Toagosei Co Ltd Antimikrobielles polypeptid und nutzung davon
AU2004281077B2 (en) 2003-10-17 2010-12-02 Inter-K Pty Limited Methods and agents for the treatment of cancer
JP4524671B2 (ja) * 2003-10-29 2010-08-18 東亞合成株式会社 抗菌ペプチド及びその利用
US7432045B2 (en) * 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides
US20050203150A1 (en) * 2004-03-09 2005-09-15 Haffar Omar K. Compounds, compositions and methods for inhibiting or treating HIV-1
JP4507080B2 (ja) * 2004-07-30 2010-07-21 東亞合成株式会社 抗菌ペプチド及びその利用
WO2006056227A1 (en) * 2004-11-27 2006-06-01 Eberhard-Karls- Universität Tübingen Universitätsklinikum Conjugates comprising the active agent and flanking or branched-chain peptides
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
EP1849474B1 (en) * 2005-02-15 2016-09-07 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EP2254901A4 (en) * 2008-02-22 2012-02-22 Inter K Pty Ltd THERAPEUTIC PEPTIDES
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
EP2454276A4 (en) 2008-07-17 2013-07-10 Inter K Pty Ltd THERAPEUTIC AGENTS
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CN105579464B (zh) 2013-08-07 2021-01-26 耶达研究及发展有限公司 能够再活化p53突变体的肽
KR20150050646A (ko) * 2013-10-29 2015-05-11 삼성전자주식회사 융합 펩타이드 및 이의 세포막투과를 위한 용도
CN108884137B (zh) * 2016-02-04 2022-04-05 耶达研究及发展有限公司 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途
WO2021167324A1 (en) * 2020-02-18 2021-08-26 Cellivery Therapeutics, Inc. Improved cell-permeable nuclear import inhibitor synthetic peptide for inhibition of cytokine storm or inflammatory disease and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
AU702323B2 (en) * 1994-03-15 1999-02-18 Selective Genetics, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
AU2638295A (en) * 1994-05-23 1995-12-18 Gideon Goldstein Compositions of transactivating proteins of human immunodeficiency virus
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000507845A5 (enExample)
JP2000515319A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2000513978A5 (enExample)
JP2000502472A5 (enExample)
JP2000511597A5 (enExample)
JP2000500874A5 (enExample)
JP2001501286A5 (enExample)
JP2001500609A5 (enExample)
JP2000502485A5 (enExample)
JP2001513754A5 (enExample)
JP2000502425A5 (enExample)
JP2002514053A5 (enExample)
JP2000502568A5 (enExample)
JP2000503534A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501229A5 (enExample)
JP2000500857A5 (enExample)
JP2000502316A5 (enExample)
JP2001501602A5 (enExample)